In an industry where women-led boardrooms remain scarce, Biocon is scripting a rare double, founded by a woman and set to be led by one again, as Kiran Mazumdar-Shaw names niece Claire Mazumdar her heir apparent.
Signalling a phased handover rather than an immediate exit, Shaw said in a post on X that Claire would “transition into my role at the right time,” adding she is “not planning to hang up my boots just yet.”
Leadership Journey
At 37, Claire represents a new generation of biotech leadership, one that sits at the intersection of deep science, venture investing, and company-building. She is currently the founder and chief executive of Bicara Therapeutics, a Boston-based, Biocon-incubated oncology company focused on next-generation bifunctional antibodies for targeted cancer therapies. Founded in 2020, Bicara has quickly scaled into a global clinical-stage biotech with a growing pipeline and international investor interest.
Before launching Bicara, Claire built experience across the biotech value chain, working at Third Rock Ventures, a prominent life sciences venture firm known for backing breakthrough science, and at Rheo Medicines, where she focused on business development and corporate strategy. Her academic credentials mirror this dual grounding in science and business: a degree in biological engineering from MIT, followed by an MBA and a PhD in cancer biology from Stanford University.
Research First
Claire’s rise also reflects a family steeped in academia and research. Her father, Ravi Mazumdar, is a University Research Chair Professor at the University of Waterloo, while her brother, Eric Mazumdar, is an assistant professor at California Institute of Technology, specialising in artificial intelligence.
Based in Boston, Claire operates at the heart of the global biotech ecosystem, bringing with her a networked, research-first approach that could shape Biocon’s next phase of growth.
Rooted in Capability
Her elevation comes at a pivotal time for Biocon, which is undergoing leadership and organisational changes, including a sharper focus on advanced biologics and innovation-led growth. For Shaw, who started Biocon in 1978 as a small enzymes venture in Bengaluru and built it into one of India’s most recognised biopharma companies, the choice of successor appears rooted as much in capability as in continuity.
Claire Mazumdar’s appointment, while still part of a phased transition, signals more than a leadership change; it reflects Biocon’s intent to align its future with cutting-edge science, global capital, and next-generation therapeutics.
(With additional inputs from Vasundhara Prakash, who is an intern with businessline)